Physician profile
Mitchell Weisberg
NPI 1578555306
$30,557.82
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,301 · 2020: $5,930 · 2021: $5,963 · 2022: $9,248 · 2023: $5,097 · 2024: $19.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,600 · Food and Beverage: $1,526 · Travel and Lodging: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,600.00 |
| Food and Beverage | $1,526.12 |
| Travel and Lodging | $989.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,801.77 | 2021-2023 | Vraylar, Ubrelvy |
| Allergan, INC. | $9,690.98 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $469.30 | 2021-2023 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $338.51 | 2019-2023 | Rexulti, Nuedexta, Abilify Maintena |
| Novo Nordisk INC | $313.59 | 2019-2023 | Wegovy |
| Lundbeck LLC | $249.11 | 2019-2023 | Abilify Maintena |
| Neurocrine Biosciences, INC. | $243.86 | 2019-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $237.02 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $228.09 | 2021-2024 | Qelbree, Qelbree |
| Alkermes, INC. | $183.99 | 2019-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $146.34 | 2019-2023 | Austedo |
| Lilly USA, LLC | $144.63 | 2022-2023 | Mounjaro |
| Pfizer INC. | $126.07 | 2019-2023 | |
| Neos Therapeutics, Lp | $124.24 | 2019-2023 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $113.46 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $106.55 | 2022-2023 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $91.13 | 2022-2023 | Auvelity |
| Shire North American Group INC | $83.92 | 2019 | |
| Avanir Pharmaceuticals, INC. | $77.62 | 2019 | |
| Biogen, INC. | $73.34 | 2021-2022 | |
| Almatica Pharma LLC | $72.11 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $66.31 | 2019-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $65.47 | 2022-2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $62.38 | 2021 | |
| Bausch Health US, LLC | $55.84 | 2019-2021 | |
| Harmony Biosciences LLC | $54.70 | 2020-2021 | |
| Corium, LLC | $48.44 | 2022 | |
| Acadia Pharmaceuticals INC | $39.30 | 2021-2023 | Nuplazid |
| Vertical Pharmaceuticals, LLC | $38.31 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $36.80 | 2023 | Horizant |
| Adlon Therapeutics L.P. | $33.64 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $23.71 | 2019 | |
| Uswm, LLC | $22.63 | 2022 | |
| Eisai INC. | $21.65 | 2021 | |
| Indivior INC. | $20.33 | 2022 | |
| Livanova USA, INC. | $20.07 | 2019 | |
| Alfasigma USA, INC. | $17.63 | 2020 | |
| Horizon Therapeutics Plc | $14.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Weisberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.